Sanofi (SNYNF)
USD 98.65
(0.0%)
USD 98.65
(0.0%)
| Year | Operating Income | Operating Income Growth |
|---|---|---|
| 2023 | 7.87 Billion EUR | 8.01% |
| 2022 | 8.5 Billion EUR | 4.63% |
| 2021 | 8.12 Billion EUR | -42.54% |
| 2020 | 14.14 Billion EUR | 352.51% |
| 2019 | 3.12 Billion EUR | -33.17% |
| 2018 | 4.67 Billion EUR | -19.42% |
| 2017 | 5.8 Billion EUR | -11.19% |
| 2016 | 6.53 Billion EUR | 16.18% |
| 2015 | 5.62 Billion EUR | -8.45% |
| 2014 | 6.14 Billion EUR | 20.31% |
| 2013 | 5.1 Billion EUR | -19.43% |
| 2012 | 6.33 Billion EUR | 10.57% |
| 2011 | 5.73 Billion EUR | -3.86% |
| 2010 | 5.96 Billion EUR | -6.36% |
| 2009 | 6.36 Billion EUR | -34.79% |
| 2008 | 9.76 Billion EUR | 64.89% |
| 2007 | 5.92 Billion EUR | 3.34% |
| 2006 | 5.72 Billion EUR | 20.63% |
| 2005 | 4.74 Billion EUR | 1658.86% |
| 2004 | -304.66 Million EUR | -109.92% |
| 2003 | 3.06 Billion EUR | 17.35% |
| 2002 | 2.61 Billion EUR | 24.21% |
| 2001 | 2.1 Billion EUR | 33.54% |
| 2000 | 1.57 Billion EUR | 62.41% |
| 1999 | 971 Million EUR | 0.0% |
| Year | Operating Income | Operating Income Growth |
|---|---|---|
| 2024 Q3 | 3.63 Billion EUR | -20.96% |
| 2024 Q1 | 1.44 Billion EUR | -69.65% |
| 2024 Q2 | 4.59 Billion EUR | 217.39% |
| 2023 Q3 | 3.21 Billion EUR | 72.73% |
| 2023 Q4 | 4.77 Billion EUR | 48.71% |
| 2023 Q1 | 2.46 Billion EUR | 26.37% |
| 2023 FY | 9.18 Billion EUR | 8.01% |
| 2023 Q2 | 1.85 Billion EUR | -24.52% |
| 2022 Q1 | 2.39 Billion EUR | 62.62% |
| 2022 Q2 | 1.43 Billion EUR | -40.26% |
| 2022 Q3 | 2.72 Billion EUR | 90.22% |
| 2022 Q4 | 1.94 Billion EUR | -28.45% |
| 2022 FY | 8.5 Billion EUR | 4.63% |
| 2021 Q2 | 1.55 Billion EUR | -24.44% |
| 2021 Q3 | 3.04 Billion EUR | 95.63% |
| 2021 Q4 | 1.47 Billion EUR | -51.55% |
| 2021 FY | 8.12 Billion EUR | -42.54% |
| 2021 Q1 | 2.05 Billion EUR | 36.38% |
| 2020 Q1 | 2.04 Billion EUR | 1819.33% |
| 2020 Q2 | 8.06 Billion EUR | 294.04% |
| 2020 Q3 | 2.61 Billion EUR | -67.58% |
| 2020 FY | 14.14 Billion EUR | 352.51% |
| 2020 Q4 | 1.5 Billion EUR | -42.27% |
| 2019 Q2 | -297 Million EUR | -121.08% |
| 2019 Q1 | 1.4 Billion EUR | 804.5% |
| 2019 FY | 3.12 Billion EUR | -33.17% |
| 2019 Q4 | -119 Million EUR | -105.58% |
| 2019 Q3 | 2.13 Billion EUR | 817.85% |
| 2018 Q1 | 1.2 Billion EUR | 60.35% |
| 2018 Q2 | 961 Million EUR | -19.98% |
| 2018 Q3 | 2.71 Billion EUR | 182.41% |
| 2018 Q4 | -200 Million EUR | -107.37% |
| 2018 FY | 4.67 Billion EUR | -19.42% |
| 2017 Q1 | 1.7 Billion EUR | 9.53% |
| 2017 Q3 | 1.97 Billion EUR | 43.85% |
| 2017 Q4 | 749 Million EUR | -62.13% |
| 2017 FY | 5.8 Billion EUR | -11.19% |
| 2017 Q2 | 1.37 Billion EUR | -19.17% |
| 2016 FY | 6.53 Billion EUR | 16.18% |
| 2016 Q2 | 1.43 Billion EUR | 24.44% |
| 2016 Q1 | 1.15 Billion EUR | 164.68% |
| 2016 Q4 | 1.55 Billion EUR | -35.05% |
| 2016 Q3 | 2.39 Billion EUR | 66.5% |
| 2015 Q3 | 1.95 Billion EUR | -2.01% |
| 2015 FY | 5.62 Billion EUR | -8.45% |
| 2015 Q1 | 1.4 Billion EUR | -16.74% |
| 2015 Q4 | 436 Million EUR | -77.7% |
| 2015 Q2 | 1.99 Billion EUR | 42.2% |
| 2014 Q2 | 1.24 Billion EUR | -12.75% |
| 2014 Q1 | 1.42 Billion EUR | 7.53% |
| 2014 FY | 6.14 Billion EUR | 20.31% |
| 2014 Q3 | 1.78 Billion EUR | 43.18% |
| 2014 Q4 | 1.68 Billion EUR | -5.55% |
| 2013 Q2 | 684 Million EUR | -53.91% |
| 2013 Q1 | 1.48 Billion EUR | 271.0% |
| 2013 FY | 5.1 Billion EUR | -19.43% |
| 2013 Q4 | 1.32 Billion EUR | -17.87% |
| 2013 Q3 | 1.61 Billion EUR | 136.4% |
| 2012 Q4 | 400 Million EUR | -81.56% |
| 2012 FY | 6.33 Billion EUR | 10.57% |
| 2012 Q1 | 2.2 Billion EUR | 133.93% |
| 2012 Q3 | 2.16 Billion EUR | 34.64% |
| 2012 Q2 | 1.61 Billion EUR | -26.97% |
| 2011 FY | 5.73 Billion EUR | -3.86% |
| 2011 Q4 | 943 Million EUR | -59.6% |
| 2011 Q1 | 1.35 Billion EUR | 468.2% |
| 2011 Q2 | 1.09 Billion EUR | -19.29% |
| 2011 Q3 | 2.33 Billion EUR | 112.96% |
| 2010 Q3 | 1.71 Billion EUR | -15.15% |
| 2010 FY | 5.96 Billion EUR | -6.36% |
| 2010 Q4 | 239 Million EUR | -86.06% |
| 2010 Q2 | 2.02 Billion EUR | 1.61% |
| 2010 Q1 | 1.98 Billion EUR | 24750.0% |
| 2009 Q1 | 2.02 Billion EUR | 171.26% |
| 2009 FY | 6.36 Billion EUR | -34.79% |
| 2009 Q4 | 8 Million EUR | -99.63% |
| 2009 Q3 | 2.14 Billion EUR | 70.46% |
| 2009 Q2 | 1.25 Billion EUR | -38.01% |
| 2008 Q1 | 2.49 Billion EUR | 116.59% |
| 2008 FY | 9.76 Billion EUR | 64.89% |
| 2008 Q4 | -2.84 Billion EUR | -209.81% |
| 2008 Q3 | 2.58 Billion EUR | 74.49% |
| 2008 Q2 | 1.48 Billion EUR | -40.51% |
| 2007 FY | 5.92 Billion EUR | 3.34% |
| 2007 Q3 | 6.96 Billion EUR | 324.78% |
| 2007 Q2 | 1.64 Billion EUR | -76.75% |
| 2007 Q1 | 7.05 Billion EUR | 143.83% |
| 2007 Q4 | -15.03 Billion EUR | -315.67% |
| 2006 Q2 | 1.06 Billion EUR | -26.53% |
| 2006 FY | 5.72 Billion EUR | 20.63% |
| 2006 Q1 | 1.44 Billion EUR | 51.77% |
| 2006 Q4 | -16.09 Billion EUR | -318.87% |
| 2006 Q3 | 7.35 Billion EUR | 592.63% |
| 2005 Q2 | 1.1 Billion EUR | 1329.32% |
| 2005 Q4 | 952.36 Million EUR | -40.07% |
| 2005 Q3 | 1.58 Billion EUR | 44.13% |
| 2005 Q1 | 77.14 Million EUR | 100.77% |
| 2005 FY | 4.74 Billion EUR | 1658.86% |
| 2004 Q1 | 2.22 Billion EUR | 169.76% |
| 2004 FY | -304.66 Million EUR | -109.92% |
| 2004 Q3 | 5.33 Billion EUR | 516.22% |
| 2004 Q2 | 865.75 Million EUR | -61.13% |
| 2004 Q4 | -10.01 Billion EUR | -287.64% |
| 2003 Q1 | 1.94 Billion EUR | 165.94% |
| 2003 Q2 | 694.41 Million EUR | -64.31% |
| 2003 Q3 | 2.41 Billion EUR | 248.12% |
| 2003 Q4 | -3.19 Billion EUR | -232.07% |
| 2003 FY | 3.06 Billion EUR | 17.35% |
| 2002 Q3 | 1.87 Billion EUR | 204.28% |
| 2002 Q2 | 615.03 Million EUR | 0.0% |
| 2002 FY | 2.61 Billion EUR | 24.21% |
| 2002 Q4 | -2.95 Billion EUR | -257.68% |
| 2001 FY | 2.1 Billion EUR | 33.54% |
| 2000 FY | 1.57 Billion EUR | 62.41% |
| 1999 FY | 971 Million EUR | 0.0% |
| Name | Operating Income | Operating Income Difference |
|---|---|---|
| AstraZeneca PLC | 8.19 Billion USD | 3.881% |
| Bristol-Myers Squibb Company PFD CONV 2 | 17.24 Billion USD | 54.327% |
| CSPC Pharmaceutical Group Limited | 7.01 Billion USD | -12.243% |
| Clarus Therapeutics Holdings, Inc. | -39.73 Million USD | 19920.296% |
| Novartis AG | 9.76 Billion USD | 19.388% |
| PT Kalbe Farma Tbk. | 3625.13 Billion USD | 99.783% |